Last week’s hot topic on ALS was the ALS Stem Cell Therapy that Showed Safety and Efficacy in Early Clinical Trials written by Magdalena Kegel.
The article refers to new and potentially promising results from its clinical investigations of NSI-566 — human spinal cord derived neural stem cells for the treatment of conditions including amyotrophic lateral sclerosis (ALS) — at the recent Phacilitate Cell & Gene Therapy World conference in Washington, D.C.
Thanks to the work of Neuralstem, a total of 30 ALS patients have been completed and met safety endpoints. NSI-566 is also currently in a Phase 1 trial for treating paralysis due to chronic spinal cord injury, as well as in a Phase 1 trial to treat paralysis from ischemic stroke.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?